Search
Now showing items 1-10 of 230
Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update.
(2020-05)
PURPOSE.—:To update key recommendations of the American Society of Clinical Oncology/College of American Pathologists estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer guideline. METHODS.—:A ...
Selective autophagy controls innate immune response through a TAK1/TAB2/SH3PX1 axis.
(CELL PRESS, 2022-01-25)
Selective autophagy is a catabolic route that turns over specific cellular material for degradation by lysosomes, and whose role in the regulation of innate immunity is largely unexplored. Here, we show that the apical ...
DRP1 levels determine the apoptotic threshold during embryonic differentiation through a mitophagy-dependent mechanism.
(CELL PRESS, 2022-06-06)
The changes that drive differentiation facilitate the emergence of abnormal cells that need to be removed before they contribute to further development or the germline. Consequently, in mice in the lead-up to gastrulation, ...
Estrogen receptor positive breast cancers have patient specific hormone sensitivities and rely on progesterone receptor.
(NATURE PORTFOLIO, 2022-06-06)
Estrogen and progesterone receptor (ER, PR) signaling control breast development and impinge on breast carcinogenesis. ER is an established driver of ER + disease but the role of the PR, itself an ER target gene, is debated. ...
ERG activity is regulated by endothelial FAK coupling with TRIM25/USP9x in vascular patterning.
(COMPANY BIOLOGISTS LTD, 2022-07-01)
Precise vascular patterning is crucial for normal growth and development. The ERG transcription factor drives Delta-like ligand 4 (DLL4)/Notch signalling and is thought to act as a pivotal regulator of endothelial cell ...
Infertility and risk of breast cancer in men: a national case-control study in England and Wales.
(BMC, 2022-05-17)
PURPOSE: Breast cancer is uncommon in men and its aetiology is largely unknown, reflecting the limited size of studies thus far conducted. In general, number of children fathered has been found a risk factor inconsistently, ...
Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups.
(2021-06-22)
In MONARCH 3, continuous dosing of abemaciclib with an aromatase inhibitor (AI) conferred significant clinical benefit to postmenopausal women with HR+, HER2- advanced breast cancer. We report data for clinically prognostic ...
Adaptive immunity to SARS-CoV-2 in cancer patients: The CAPTURE study.
(AMER ASSOC CANCER RESEARCH, 2020-03-01)
Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic.
(2020-01)
Many patients with ER+ HER2- primary breast cancer are being deferred from surgery to neoadjuvant endocrine therapy (NeoET) during the COVID-19 pandemic. We have collated data from multiple international trials of presurgical ...
Assessment of Ki67 in Breast Cancer: Updated Recommendations from the International Ki67 in Breast Cancer Working Group.
(2020-12-28)
Ki67 immunohistochemistry, commonly used as a proliferation marker in breast cancer, has limited value for treatment decisions due to questionable analytical validity. The International Ki67 Working Group (IKWG) consensus ...